leisure time
Introducing STAT’s Biotech Q2 Scorecard, our emoji-enabled means of tracking 12 make-or-break events expected over the next three months.
When each clinical trial or FDA decision crosses the wires, we’ll add in the appropriate rocket ship, grimace face, bulging bicep or broken heart — whatever captures the mood.
advertisement
Read on for brief explanations of what we’re watching for from each company.
Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!
GET STARTED Log In
Previous article：
Novo Holdings to buy drug manufacturer Catalent in $16.5B deal
Next article： The cancer drug shortage isn’t new — and neither are the solutions
Next article： The cancer drug shortage isn’t new — and neither are the solutions
